New joint pain during perimenopause or after menopause is common, but it should not automatically be labelled “age-related wear and tear". Menopausal arthralgia describes joint pain and stiffness that emerge or worsen around the menopausal transition without another diagnosis fully explaining the presentation. It may occur alone or alongside hot flushes, sleep disturbance, fatigue and reduced exercise tolerance. However, menopause can also coincide with osteoarthritis, inflammatory arthritis, tendinopathy, osteoporosis or a systemic illness. The clinician’s task is therefore to recognise the hormonal context without overlooking a treatable musculoskeletal or medical disorder.

Why can joint pain appear around menopause?

Oestrogen receptors are present in cartilage, bone, synovium, muscle, tendon and other connective tissues. Falling and fluctuating oestrogen levels may influence inflammatory signalling, pain sensitivity, collagen turnover and tissue recovery. At the same time, menopause-related sleep disruption, loss of muscle mass, reduced physical activity and changes in body composition can lower a person’s capacity to tolerate everyday loading. These interacting factors help explain why symptoms may feel widespread or disproportionate to a single local tissue lesion (Wright et al., 2024).

The association is clinically plausible but not exclusive or perfectly predictable. “Menopausal arthralgia” is a symptom description rather than a single confirmed pathological entity, and no laboratory test establishes it. The term should be used only after a reasoned assessment. A patient may have a predominantly menopause-associated pain presentation, a coincidental joint disorder, or both.

Clinical presentation and important differential diagnoses

Patients often describe new aching, stiffness after rest, reduced ease of movement or pain affecting several regions. The hands, knees, hips, shoulders and spine may be involved. Symptoms may fluctuate and may parallel vasomotor symptoms, poor sleep or changes in menstrual pattern. There may be tenderness and functional limitation, but persistent objective synovitis is not a typical feature of uncomplicated arthralgia.

The pattern matters more than the patient’s age alone.

Urgent medical assessment is required for a hot, acutely swollen joint; fever or systemic illness; inability to bear weight after trauma; suspected fracture; progressive neurological deficit; unexplained weight loss; or severe night pain that is not altered by position. Prompt rheumatology or medical referral is appropriate when there is persistent joint swelling, prolonged morning stiffness, small-joint symmetry, rash, eye inflammation or other systemic features. Swelling not explained by trauma should raise suspicion of early inflammatory arthritis rather than being attributed to menopause (Combe et al., 2007).

Physiotherapy assessment of new joint pain

Assessment begins with a timeline. Ask whether symptoms started during perimenopause, after the final menstrual period, following surgical menopause or after a change in hormone therapy. Record the joints involved, pain behaviour, morning-stiffness duration, swelling, night symptoms, fatigue and the relationship to activity. A brief menopause history should include menstrual change, hot flushes, sleep, mood and genitourinary symptoms. Medical history should screen for psoriasis, inflammatory bowel disease, autoimmune disease, cancer, infection, trauma, medication changes and family history of inflammatory arthritis or osteoporosis.

The physical examination should be hypothesis-led. Observe swelling, redness, deformity, gait and movement strategy. Palpate for warmth, joint-line tenderness and tendon tenderness; assess active and passive range, muscle strength and the response to functional loading. Functional tests may include sit-to-stand, stair negotiation, grip tasks, squat or balance assessment, selected according to the symptomatic region. A body chart, pain rating and a patient-reported measure such as the Patient-Specific Functional Scale can provide a baseline for review. Regional special tests should confirm or challenge a clinical hypothesis rather than form a routine checklist (Magee & Manske, 2021).

Blood tests and imaging are not required merely because pain began around menopause. Medical investigations should be targeted to the differential diagnosis. Depending on the presentation, these may include inflammatory markers, rheumatoid factor, anti-CCP antibodies, thyroid testing, vitamin D assessment, radiographs or ultrasound. Bone-health assessment and dual-energy X-ray absorptiometry may be indicated according to age, premature menopause, fracture history and other osteoporosis risks. Importantly, normal inflammatory markers do not by themselves exclude early inflammatory arthritis.

Physiotherapy and self-management

Education should validate the symptoms while reducing fear. Explain that hormonal change may influence pain and tissue capacity, but safe movement does not “wear out” the joints. Complete rest commonly increases stiffness and deconditioning. Management should restore confidence and gradually rebuild the capacity needed for work, self-care and recreation.

Exercise is individualised to the dominant impairment and any established joint diagnosis. A practical programme commonly includes:

progressive resistance training two or three days per week, initially using tolerable ranges and major muscle groups;
regular aerobic activity such as walking, cycling or swimming, accumulated according to current capacity;
joint-specific mobility where stiffness limits function;
balance and weight-bearing exercise when falls or bone health are concerns; and
graded exposure to previously painful tasks rather than indefinite avoidance.

A useful starting dose is one to three sets of 6–12 repetitions for selected strengthening exercises, with load, range or volume progressed when technique is controlled and the response is acceptable. This is a clinical starting point, not a fixed menopause protocol. Mild muscular discomfort that settles is generally acceptable; marked swelling, escalating pain, loss of function or a response that remains clearly worse the following day warrants dose reduction and reassessment. Longer-term activity can progress towards 150–300 minutes of moderate aerobic activity weekly plus muscle strengthening on at least two days, as ability allows (Bull et al., 2020).

Sleep support, pacing and sustainable weight management may reduce the total symptom burden. Heat or cold may provide short-term comfort according to preference. If osteoarthritis is diagnosed, exercise, self-management and—when relevant—weight reduction remain core treatments (Kolasinski et al., 2020). Analgesics, topical or oral anti-inflammatory medicines, injections and supplements require medical or pharmacy review because suitability depends on the diagnosis, comorbidities and concurrent medication.

Where does menopausal hormone therapy fit?

Menopausal hormone therapy (MHT), also called hormone replacement therapy, may reduce joint symptoms in some patients, especially when pain occurs with other bothersome menopausal symptoms. In a Women’s Health Initiative analysis, oestrogen alone produced a modest sustained reduction in joint-pain frequency compared with placebo; this finding does not mean that MHT is a universal treatment for unexplained joint pain (Chlebowski et al., 2013).

Physiotherapists should neither prescribe MHT nor imply that symptom improvement confirms the diagnosis. Instead, they can document the musculoskeletal presentation and recommend discussion with a menopause-informed medical clinician. The decision should consider the patient’s symptoms, uterine status, age, time since menopause, personal preferences and individual risks. Current menopause guidance recognises joint and muscle pain as possible menopausal symptoms, while emphasising individualised discussion of treatment benefits and risks (National Institute for Health and Care Excellence [NICE], 2024). Exercise and medical management are complementary: MHT does not replace progressive loading, and exercise does not replace appropriate investigation or menopause care.

Viva-ready summary

Menopausal arthralgia is new or worsening joint pain associated temporally with the menopausal transition when no alternative condition fully explains the symptoms. Oestrogen fluctuation may affect inflammation, pain processing and connective-tissue health, while sleep disturbance, sarcopenia and reduced activity can amplify symptoms. Diagnosis is clinical and requires differentiation from osteoarthritis, inflammatory arthritis, tendinopathy, fibromyalgia and fracture. Physiotherapy management combines education, progressive strengthening, aerobic activity, mobility work, symptom-guided loading and attention to sleep and bone health. Persistent swelling, prolonged morning stiffness, systemic illness, trauma or neurological signs require medical investigation or referral. MHT may modestly improve joint pain in some patients but should be considered through individualised medical shared decision-making.

One-line recall point: New joint pain around menopause may be hormone-associated, but swelling, prolonged morning stiffness and systemic features demand an alternative diagnosis until proven otherwise.

References

Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., Dempsey, P. C., DiPietro, L., Ekelund, U., Firth, J., Friedenreich, C. M., Garcia, L., Gichu, M., Jago, R., Katzmarzyk, P. T., ... Willumsen, J. F. (2020). World Health Organization 2020 guidelines on physical activity and sedentary behaviour. British Journal of Sports Medicine, 54(24), 1451–1462. https://doi.org/10.1136/bjsports-2020-102955

Chlebowski, R. T., Cirillo, D. J., Eaton, C. B., Stefanick, M. L., Pettinger, M., Carbone, L. D., Johnson, K. C., Simon, M. S., Woods, N. F., & Wactawski-Wende, J. (2013). Oestrogen alone and joint symptoms in the Women’s Health Initiative randomized trial. Menopause, 20(6), 600–608. https://doi.org/10.1097/GME.0b013e31828392c4

Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M. W., Klareskog, L., Machold, K., Martin-Mola, E., Nielsen, H., Silman, A., Smolen, J., Yazici, H., & EULAR Standing Committee for International Clinical Studies Including Therapeutics. (2007). EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases, 66(1), 34–45. https://doi.org/10.1136/ard.2005.044354

Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., Gellar, K., Harvey, W. F., Hawker, G., Herzig, E., Kwoh, C. K., Nelson, A. E., Samuels, J., Scanzello, C., White, D., ... Reston, J. (2020). 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care & Research, 72(2), 149–162. https://doi.org/10.1002/acr.24131

Magee, D. J., & Manske, R. C. (2021). Orthopedic physical assessment (7th ed.). Elsevier.

National Institute for Health and Care Excellence. (2024). Menopause: Identification and management (NICE Guideline NG23). https://www.nice.org.uk/guidance/ng23

Wright, V. J., Schwartz, L., & Hartzell, F. M. (2024). The musculoskeletal syndrome of menopause. Climacteric, 27(5), 466–472. https://doi.org/10.1080/13697137.2024.2380363